title: CD20+ lymphocytes in renal allografts are associated with poor graft survival in pediatric patients.
abstract: BACKGROUND
  The presence of CD20+ lymphocyte renal allograft infiltrates has been associated with steroid-resistant rejection and poor graft survival. We quantified the number of CD20+ lymphocytes in renal allograft biopsies and correlated the results with graft survival. We also determined the relationships between CD20+ lymphocytes and acute cellular rejection versus antibody-mediated rejection.
  
  
  METHODS
  We examined 45 biopsy samples from 31 pediatric patients biopsied for suspicion of rejection from November 2001 to November 2004. Immunohistochemical staining for CD20 and C4d was performed on all biopsies; CD20+ cell density per high-power field (hpf) was determined for each core. Patient graft status was followed postbiopsy and documented for graft survival or failure using the cutoff date of December 31, 2005.
  
  
  RESULTS
  Patients with 2-10 and 11-100 CD20+ cells/hpf had worse graft survival in Kaplan-Meier analysis with a hazard ratio 4.56 (CI 1.07-19.35) two years postbiopsy compared to those with 0-1 cells/hpf (P = 0.02). The presence of CD20+ lymphocytes was significantly associated with acute cellular rejection (P = 0.0001) and not associated with antibody-mediated rejection (P = 0.16). Receiver-operating curve analysis confirmed > or =3 cells/hpf correlating with acute cellular rejection, yielding sensitivity 90% and specificity 76%.
  
  
  CONCLUSIONS
  This study shows a significant 4.5-fold risk of graft failure at two years postbiopsy with presence of > or =2 CD20+ cells/hpf. Moreover, > or =3 CD20+ lymphocytes were highly associated with acute cellular rejection. They may be functioning as professional antigen-presenting cells in the graft. In steroid-refractory cellular rejections, therapies that target B cells may prolong graft survival.
authors.affiliation: Mattel Children's Hospital at UCLA, Department of Pediatrics, Division of Nephrology, UCLA Medical Center, Los Angeles, CA, USA.
authors.forename: Eileen W
authors.initials: EW
authors.lastname: Tsai
authors.forename: Pornpimol
authors.initials: P
authors.lastname: Rianthavorn
authors.forename: David W
authors.initials: DW
authors.lastname: Gjertson
authors.forename: William D
authors.initials: WD
authors.lastname: Wallace
authors.forename: Elaine F
authors.initials: EF
authors.lastname: Reed
authors.forename: Robert B
authors.initials: RB
authors.lastname: Ettenger
mesh_terms: D000293:Adolescent; D000328:Adult; D018951:Antigens, CD20 / Q000032:analysis*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006084:Graft Rejection / Q000139:chemically induced / Q000276:immunology*; D006085:Graft Survival / Q000187:drug effects / Q000276:immunology*; D006801:Humans; D016030:Kidney Transplantation / Q000276:immunology*; D008214:Lymphocytes / Q000276:immunology*; D008297:Male; D013256:Steroids / Q000009:adverse effects
chemical_list: D018951:Antigens, CD20; D013256:Steroids